The recovery that has come in the equity market during the last 3 months is now showing its effect on the mutual fund market. Particularly in equity funds, there is a stir now. In every category of equity segment, now the returns of the last 3 months have reached double digit. At the same time, if you talk about different schemes, then investors have got 40% returns in 3 months. Experts say that the year 2020 has also been a volatile one for the mutual fund markets. But this is the right time to take advantage of low valuation. Experts are advising to choose large cap, multi cap and large cap and mid cap in equity equity segment. He says that in the recovery phase of the economy, firstly large caps perform better.
Axis Blue chip Fund
10 Year Return: 10.80%
Value of 1 lakh investment in 10 years: 2.79 lakh
Value of 10 thousand monthly SIP in 10 years: 22.36 lakhs
Minimum investment: Rs 5000
Minimum SIP: 1000 rupees
Launch Date: 05 January 2010
Return since launch: 11.07% Asset: 14,522 Crore (June 30, 2020)
Expense Ratio: 1.70% (June 30, 2020)
Risk Grade: Low
Return Grade: High
Holding: HDFC Bank, Infosys, Kotak Mahindra Bank, Bajaj Finance
Mirae Asset Emerging Blue chip Fund
10 Year Return: 18.15%
Value of 1 lakh investment in 10 years: 5.30 lakh
Value of 10 thousand monthly SIP in 10 years: 31.67 Lakh
Minimum investment: Rs 5000
Minimum SIP: 1000 rupees Launch Date: 09 July 2008
Return since launch: 18.45% Asset: 9,834 Crore (June 30, 2020)
Expense Ratio: 1.76% (June 30, 2020)
Risk Grade: Low
Return Grade: High
Holding: HDFC Bank, Reliance Industries, ICICI Bank, Infosys
Canara Robeco Emerging Equities Fund
10 Year Return: 15.52%
Value of 1 lakh investment in 10 years: 4.23 lakh
10 thousand monthly SIP value in 10 years: 27.83 lakh
Minimum investment: Rs 5000
Minimum SIP: 1000 rupees
Launch Date: 01 March 2005
Return since launch: 15.63% Asset: 5,162 Crore (June 30, 2020)
Expense Ratio: 1.97% (June 30, 2020)
Risk Grade: Average Return
Grade: High
Holding: Reliance Industries, HDFC Bank, ICICI Bank, Airtel
Nippon India Pharma Fund
From October 2019, Reliance Mutual Fund has been renamed to Nippon India Mutual Fund. Nippon Life has acquired a majority (75%) stake in Reliance Nippon Asset Management (RNAM). The company will continue its operations without any change in structure and management. The scheme is managed by Nippon Mutual Fund and was launched on 05 June 2004. The scheme invests its fund money in equity and fixed income instruments of pharma and related companies and thus seeks to earn consistent returns. The risk taking potential is that of Reliance / Nippon India Pharma Fund. The portfolio of this fund is a combination of large-cap and stock companies of medium-sized companies. Mr. Shailesh Raj Bhan is the fund manager who ignores the performance of Reliance Pharma Fund. On January 31, 2018, some of the stocks in the portfolio of Nippon India Pharma Fund included Thyrocare Technologies Limited, Sun Pharmaceutical Industries Limited, Cipla Limited and Torrent Pharmaceuticals Limited. This is an open ended scheme.
Min SIP Investment Rs 100.
